Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Sep 10, 2021 10:45am
288 Views
Post# 33839608

RE:RE:IBD update ... market size

RE:RE:IBD update ... market size
Nick80 wrote: that is very positive indeed, however our potential IBD drug is many years away from being relevant and to be come relevant it has to pass so many hurdles. I cant imagine how many raises and interviews and trails are necessary to bring this forward... and one event can kill it on the track.

I am desperate for some good news to but that ain't good enough.I didn't come to terms being overextended in this risky play and still have to digest what happend to ate 346 which gave me a negative return of 80% of my investment just because I was to hopeful.

This might well be 90 to 95% soon and I really hope not.



Nick - please forgive - but I don't look at share price as an indicator (unless I'm selling).
That being said ... the question really is ... is there anything of value here?
That's for everyone to decide on their own - no one can make that decisions for you.

As far as I'm concerned, I look at OTENA as being in a very unique and interesting place.  GI safety and CV saftely are right where we want it.  Has OTENA failed?  No.  What it's guilty of ... is ... not knowing where the bottom dose is.  Once we know where the bottom is - then we'll be told the path forward ... low-dose, high-dose or both options (IMO).

In parallel, we need to build a drug pipeline and that's where IBD comes in.  Forget how far it is in the future but cash today will help them build the pipeline of tomorrow.  Gotta start somewhere and gotta start yesterday.

If I get what I'm looking for ... I'm going to get a more improved OTENA - future replacement for OTENA - future 340 replacement at 20 year IPs - and - an IBD drug that can rock this world, way beyond IBD indications.  These are all valuable w.r.t negotiations over the next 5 years IMO.

What I'm saying is ... if you want a chance at being acquired as a business ... for a very nice valuation (one day) ... you have to build that company with many parallel opportunities.  That's where you reduce risk.

Sure ... one step at a time ... we need October's update. But in the meantime ... you build a much larger organization with a drug development funnel.  Afterall ... that's what ATE is supposed to become - a drug creation powerhouse.

That's why I'm here and I like that strategy.
<< Previous
Bullboard Posts
Next >>